Drugs / Regulatory T cells
Regulatory T cells
Trials 9 · a red edge is where a trial was stopped
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-10-22 | Daiichi Sankyo | Daiichi Sankyo Initiates Phase 1 Trial with Immuno-Oncology Therapy DS-1055 Targeting GARP on Activated Regulatory T Cells daiichisankyo.com ↗ |
| 2015-04-14 | Pfizer | REGiMMUNE Announces Collaboration with JDRF and Pfizer Inc. for Type 1 Diabetes Prevention and Treatment Promoting Regulatory T-Cells pfizer.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Regulatory T cells | “Patients received an infusion of 2 × 106/kg donor regulatory T cells on day -4 followed by 1 × 106/kg donor conventional T cells on day -1 and a mean of 10.7 × 106 ± 3.4 ×...” PMID 33646302 ↗ Mar 2021 |
| Known as | Treg | “Regulatory T-Cells (Treg)” NCT01660607 ↗ |
| Known as | Treg cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01163201 ↗ |
| Known as | Tregs | “The patient received a single infusion of 1×106 autologous, ex vivo expanded, polyclonal Tregs per kilogram of body weight, and the clinical, biochemical, endoscopic and...” PMID 35428657 ↗ Apr 2022 |
| Modality | Cell therapy | “These are the enriched but naturally-occurring regulatory T cells.” NCT01050764 ↗ |
| Route | Other | “Given by infusion on Day 0 after transplantation” NCT01163201 ↗ |